Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 145


CorA is a copper repressible surface-associated copper(I)-binding protein produced in Methylomicrobium album BG8.

Johnson KA, Ve T, Larsen O, Pedersen RB, Lillehaug JR, Jensen HB, Helland R, Karlsen OA.

PLoS One. 2014 Feb 3;9(2):e87750. doi: 10.1371/journal.pone.0087750. eCollection 2014.


CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.

Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud Ø.

Oncotarget. 2013 Sep;4(9):1438-48.


Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.

Birkeland E, Busch C, Berge EO, Geisler J, Jönsson G, Lillehaug JR, Knappskog S, Lønning PE.

Clin Exp Metastasis. 2013 Oct;30(7):867-76. doi: 10.1007/s10585-013-9587-4. Epub 2013 May 15.


Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.

Berge EO, Huun J, Lillehaug JR, Lønning PE, Knappskog S.

Biochim Biophys Acta. 2013 Mar;1830(3):2790-7.


The Methylococcus capsulatus (Bath) secreted protein, MopE*, binds both reduced and oxidized copper.

Ve T, Mathisen K, Helland R, Karlsen OA, Fjellbirkeland A, Røhr ÅK, Andersson KK, Pedersen RB, Lillehaug JR, Jensen HB.

PLoS One. 2012;7(8):e43146. doi: 10.1371/journal.pone.0043146. Epub 2012 Aug 20.


Human protein N-terminal acetyltransferase hNaa50p (hNAT5/hSAN) follows ordered sequential catalytic mechanism: combined kinetic and NMR study.

Evjenth RH, Brenner AK, Thompson PR, Arnesen T, Frøystein NÅ, Lillehaug JR.

J Biol Chem. 2012 Mar 23;287(13):10081-8. doi: 10.1074/jbc.M111.326587. Epub 2012 Feb 6.


Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma.

Myklebust LM, Akslen LA, Varhaug JE, Lillehaug JR.

Thyroid. 2011 Nov;21(11):1217-25. doi: 10.1089/thy.2010.0186. Epub 2011 Oct 18.


The human N-alpha-acetyltransferase 40 (hNaa40p/hNatD) is conserved from yeast and N-terminally acetylates histones H2A and H4.

Hole K, Van Damme P, Dalva M, Aksnes H, Glomnes N, Varhaug JE, Lillehaug JR, Gevaert K, Arnesen T.

PLoS One. 2011;6(9):e24713. doi: 10.1371/journal.pone.0024713. Epub 2011 Sep 15.


Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency.

Rope AF, Wang K, Evjenth R, Xing J, Johnston JJ, Swensen JJ, Johnson WE, Moore B, Huff CD, Bird LM, Carey JC, Opitz JM, Stevens CA, Jiang T, Schank C, Fain HD, Robison R, Dalley B, Chin S, South ST, Pysher TJ, Jorde LB, Hakonarson H, Lillehaug JR, Biesecker LG, Yandell M, Arnesen T, Lyon GJ.

Am J Hum Genet. 2011 Jul 15;89(1):28-43. doi: 10.1016/j.ajhg.2011.05.017. Epub 2011 Jun 23. Erratum in: Am J Hum Genet. 2011 Aug 12;89(2):345.


Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE.

PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249.


Proteome-derived peptide libraries allow detailed analysis of the substrate specificities of N(alpha)-acetyltransferases and point to hNaa10p as the post-translational actin N(alpha)-acetyltransferase.

Van Damme P, Evjenth R, Foyn H, Demeyer K, De Bock PJ, Lillehaug JR, Vandekerckhove J, Arnesen T, Gevaert K.

Mol Cell Proteomics. 2011 May;10(5):M110.004580. doi: 10.1074/mcp.M110.004580. Epub 2011 Mar 7.


Depletion of the human Nα-terminal acetyltransferase A induces p53-dependent apoptosis and p53-independent growth inhibition.

Gromyko D, Arnesen T, Ryningen A, Varhaug JE, Lillehaug JR.

Int J Cancer. 2010 Dec 15;127(12):2777-89. doi: 10.1002/ijc.25275.


RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer.

Knappskog S, Myklebust LM, Busch C, Aloysius T, Varhaug JE, Lønning PE, Lillehaug JR, Pendino F.

Ann Oncol. 2011 Oct;22(10):2208-15. doi: 10.1093/annonc/mdq737.


The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.

Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS, Stoltenberg C, Romundstad P, Hveem K, Lillehaug JR, Vatten L, Devilee P, Dørum A, Lønning PE.

Cancer Cell. 2011 Feb 15;19(2):273-82. doi: 10.1016/j.ccr.2010.12.019.


Alterations of the retinoblastoma gene in metastatic breast cancer.

Berge EO, Knappskog S, Lillehaug JR, Lønning PE.

Clin Exp Metastasis. 2011 Mar;28(3):319-26. doi: 10.1007/s10585-011-9375-y. Epub 2011 Jan 21.


Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers.

Berge EO, Knappskog S, Geisler S, Staalesen V, Pacal M, Børresen-Dale AL, Puntervoll P, Lillehaug JR, Lønning PE.

Mol Cancer. 2010 Jul 1;9:173. doi: 10.1186/1476-4598-9-173.


MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.

Busch C, Geisler J, Lillehaug JR, Lønning PE.

Eur J Cancer. 2010 Jul;46(11):2127-33. doi: 10.1016/j.ejca.2010.04.023. Epub 2010 Jun 10.


Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine.

Busch C, Geisler J, Knappskog S, Lillehaug JR, Lønning PE.

J Invest Dermatol. 2010 Oct;130(10):2514-6. doi: 10.1038/jid.2010.138. Epub 2010 May 27. No abstract available.


Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.

Jönsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringnér M, Lillehaug JR, Borg A, Lønning PE.

Clin Cancer Res. 2010 Jul 1;16(13):3356-67. doi: 10.1158/1078-0432.CCR-09-2509. Epub 2010 May 11.


Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity.

Berge EO, Staalesen V, Straume AH, Lillehaug JR, Lønning PE.

Biochim Biophys Acta. 2010 Mar;1803(3):386-95. doi: 10.1016/j.bbamcr.2010.01.005. Epub 2010 Jan 15.

Items per page

Supplemental Content

Loading ...
Support Center